Free Trial

Bioventus (NYSE:BVS) Coverage Initiated by Analysts at Cantor Fitzgerald

Bioventus logo with Medical background

Cantor Fitzgerald assumed coverage on shares of Bioventus (NYSE:BVS - Free Report) in a research report report published on Monday morning, Marketbeat reports. The firm issued an overweight rating and a $12.00 target price on the stock.

A number of other equities research analysts also recently issued reports on BVS. Craig Hallum set a $15.00 price objective on shares of Bioventus and gave the stock a "buy" rating in a research note on Wednesday, May 7th. Canaccord Genuity Group reiterated a "buy" rating and set a $15.00 price target on shares of Bioventus in a research report on Monday, March 17th.

Check Out Our Latest Research Report on BVS

Bioventus Price Performance

Shares of NYSE BVS traded down $0.20 during mid-day trading on Monday, reaching $6.82. The company had a trading volume of 428,692 shares, compared to its average volume of 431,357. The company has a debt-to-equity ratio of 1.85, a quick ratio of 0.99 and a current ratio of 1.41. Bioventus has a one year low of $5.73 and a one year high of $14.38. The firm has a market cap of $560.22 million, a price-to-earnings ratio of -11.18 and a beta of 0.84. The business's 50-day simple moving average is $6.72 and its 200 day simple moving average is $8.60.

Insider Activity

In other news, CFO Mark Leonard Singleton sold 3,875 shares of Bioventus stock in a transaction on Friday, April 11th. The stock was sold at an average price of $7.57, for a total value of $29,333.75. Following the transaction, the chief financial officer owned 141,088 shares in the company, valued at approximately $1,068,036.16. This trade represents a 2.67% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 33.00% of the company's stock.

Hedge Funds Weigh In On Bioventus

Hedge funds and other institutional investors have recently modified their holdings of the business. Tower Research Capital LLC TRC increased its stake in shares of Bioventus by 106.1% in the 4th quarter. Tower Research Capital LLC TRC now owns 3,469 shares of the company's stock valued at $36,000 after purchasing an additional 1,786 shares during the last quarter. GAMMA Investing LLC increased its stake in shares of Bioventus by 3,228.7% in the 1st quarter. GAMMA Investing LLC now owns 5,792 shares of the company's stock valued at $53,000 after purchasing an additional 5,618 shares during the last quarter. Russell Investments Group Ltd. increased its stake in shares of Bioventus by 23,761.5% in the 1st quarter. Russell Investments Group Ltd. now owns 6,204 shares of the company's stock valued at $57,000 after purchasing an additional 6,178 shares during the last quarter. KLP Kapitalforvaltning AS acquired a new stake in shares of Bioventus during the 4th quarter valued at $75,000. Finally, Quantbot Technologies LP acquired a new stake in shares of Bioventus during the 4th quarter valued at $103,000. Institutional investors own 62.94% of the company's stock.

Bioventus Company Profile

(Get Free Report)

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.

Featured Articles

Should You Invest $1,000 in Bioventus Right Now?

Before you consider Bioventus, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bioventus wasn't on the list.

While Bioventus currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Made in America Stocks Under $20 You Need to See!
3 Cheap Growth Stocks Set to Explode This Summer
The Next NVIDIA? Quantum Computing Stocks Set for Explosive Growth

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines